VivoSeq
Other

Biologics

0

Pipeline Programs↗

2

Active Trials↗

1

Companies Involved↗

Biologics is an early-stage landscape with 0 programs across 1 company. The most active players are Bristol-Myers Squibb.

Intelligence

Pipeline Metrics

Competitive Density

10/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Bristol-Myers Squibb logo

Bristol-Myers Squibb

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

7

clinical trials

Unknown status3 · 43%
Completed2 · 29%
Recruiting2 · 29%

Clinical Trials

Trial Activity

7 trials

Duobrii in Combination With Biologics
Recruiting·PPsoriasis Treatment Center of Central New Jersey·Phase 4·NCT04119102·25 enrolled
Prediction Model for Response to Biologics and Small Molecular Agent for UC
Recruiting·—·N/A·NCT05186623·300 enrolled
Pharmacokinetic Study to Compare the Blood Levels of Abatacept Manufactured at Lonza Biologics to the Blood Levels of Abatacept Manufactured at the Devens, Massachusetts (MA) Facility of Bristol-Myers Squibb
Completed·Bristol-Myers Squibb logoBristol-Myers Squibb·Phase 1·NCT01439204·223 enrolled
Clinical Study Using Biologics to Improve Multi OIT Outcomes (COMBINE)
Completed·SStanford University·Phase 2·NCT03679676·108 enrolled
A Clinical Study to Evaluate the Efficacy of Biologics in SpA
Unknown status·TThe University of Hong Kong-Shenzhen Hospital·N/A·NCT04399382·40 enrolled
Multi-omics to Predict Responses to Biologics in IBD
Unknown status·SSixth Affiliated Hospital, Sun Yat-sen University·N/A·NCT05542459·1,050 enrolled
Measurement of the Structural Efficacy in Active RA Patients Treated With Sarilumab in Combination With MTX and Naive to Biologics
Unknown status·GGaylis, Norman B., M.D.·Phase 3·NCT03535402·20 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)